Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Université de Côte d'Azur, Chu De Nice
InventorsThierry Passeron, Florence Joly
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Claims4
A method for treating Vitiligo disorder and/or repigmenting a Vitiligo lesion in a subject having a Vitiligo area resistant to repigmentation after treatment with phototherapy, topical steroid or calcineurin inhibitor by inducing differentiation of melanocyte stem cells in hair follicles and dermis, comprising administering to the subject an activator of at least one protein of the WNT signaling pathway which activates PAX3 (transcription factor 3 of the paired box (PAX) family), wherein said activator is administered to the subject topically.
Dependencies are inferred from the claim text.